This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Klouche, M. Articles by Bhakdi, S. Search for Related Content PubMed PubMed Citation Articles by Klouche, M. Articles by Bhakdi, S. Related Collections Smooth muscle proliferation and differentiation

(Circulation. 2000;101:1799.)
© 2000 American Heart Association, Inc.

Clinical Investigation and Reports

Enzymatically Degraded, Nonoxidized LDL Induces Human Vascular Smooth Muscle Cell Activation, Foam Cell Transformation, and Proliferation

Mariam Klouche, MD; Stefan Rose-John, PhD; Walther Schmiedt, MD; Sucharit Bhakdi, MD

From the Institute of Medical Microbiology (M.K., S.B.), Department of Internal Medicine (S.R.-J.), Section of Pathophysiology and Department of Heart and Thoracic Surgery (W.S.), University of Mainz, Germany.

Correspondence to Dr Mariam Klouche, Institute of Medical Microbiology, University of Mainz, Hochhaus am Augustusplatz, 55101 Mainz, Germany. E-mail: klouche{at}mail.uni-mainz.de

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background—Enzymatic, nonoxidative modification transforms LDL to an atherogenic molecule (E-LDL) that activates complement and macrophages and is present in early atherosclerotic lesions.

Methods and Results—We report on the atherogenic effects of E-LDL on human vascular smooth muscle cells (SMC). E-LDL accumulated in these cells, and this was accompanied by selective induction of monocyte chemotactic protein-1 in the absence of effects on the expression of interleukin (IL)-8, RANTES, or monocyte inflammatory proteins-1 and -ß). Furthermore, E-LDL stimulated the expression of gp130, the signal-transducing chain of the IL-6 receptor (IL-6R) family, and the secretion of IL-6. E-LDL invoked mitogenic effects on SMC through 2 mechanisms. First, an autocrine mitogenic circuit involving platelet-derived growth factor and fibroblast growth factor-ß was induced. Second, upregulation of gp130 rendered SMC sensitive to transsignaling through the IL-6/sIL-6R activation pathway. Because E-LDL promoted release of both IL-6 and sIL-6R from macrophages, application of macrophage cell supernatants to prestimulated SMC provoked a pronounced and sustained proliferation of the cells.

Conclusions—E-LDL can invoke alterations in SMC that are characteristic of the evolving atherosclerotic lesion.

Key Words: atherosclerosis • lipoproteins • cells • muscle, smooth • enzymes

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Atherosclerosis is an inflammatory disease¹ in which a cascade of events involving C-reactive protein (CRP) deposition, complement activation, selective accumulation of monocytes and T-lymphocytes, activation of endothelial cells, and expression of chemokines and cytokines is elicited locally by tissue-deposited, modified lipoproteins.²

Mainstream researchers regard oxidation to be the central process that transforms LDL into an atherogenic molecule. We are advancing an alternative concept,³ however, that has evolved from the need to account for a number of findings that have not been consistent with the oxidation paradigm. We propose that LDL stranded in the connective matrix of the intima is subject to enzymatic, nonoxidative degradation by ubiquitous proteases and cholesterol esterase. Enzymatically altered LDL (E-LDL) is atherogenic because it binds CRP, thus activating complement,^{4 5} and because it provokes macrophage foam cell formation⁴ and liberation of monocyte chemotactic protein-1 (MCP-1) and interleukin (IL)-6.⁶ At high concentrations, E-LDL elicits cytotoxic effects on macrophages that may be due to apoptosis.⁶ Further, E-LDL induces upregulation of adhesion molecules on endothelial cells and promotes the selective transmigration of monocytes and T cells to the lesion.⁷ With the use of specific monoclonal antibodies, E-LDL has been shown to be present in all early human lesions.⁸ E-LDL colocalized extracellularly with CRP and with terminal complement complexes.^{5 8 9} Importantly, lipoprotein derivatives that were isolated from early atherosclerotic lesions indeed exhibited ultrastructural and biochemical features in common with E-LDL^{10 11 12} and had the capacity to activate complement.¹⁰

Because E-LDL is now emerging as a novel candidate to assume the role of the prime atherogenic species, we proceeded to investigate whether its atherogenic effects may extend to smooth muscle cells (SMC). We show that E-LDL indeed alters SMC homeostasis and identify a novel pathway that could be responsible for SMC proliferation. Thus, E-LDL can produce classic changes in SMC function that are characteristic of the developing atherosclerotic lesion.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Preparation and Culture of Human Vascular SMC
Human vascular SMC were cultured from pieces of human aortas obtained during aneurysm surgery (15 donors, mean age 72 years, 10 men and 5 women) by outgrowth from explanted media fragments.¹³ More than 90% of the cells were positive for -actin (clone 1A4, Sigma) and showed the typical "hill-and-valley" morphology. As a negative control, cells cultivated in DMEM supplemented with the enzyme mix used for the preparation of E-LDL were used. All experiments were performed after <5 passages of culture.

Lipoprotein Isolation and Modifications
Native human LDL was isolated,⁶ and enzymatic modification with trypsin, cholesterol esterase, and neuraminidase was undertaken as described.⁴ The ensuing E-LDL preparations comprised a population of fused LDL particles with diameters of 25 to 500 nm. The apolipoprotein B was extensively degraded, and the ratio of free to esterified cholesterol was 1:1. The concentration of free fatty acids was not determined. Phospholipids remained quantitatively associated with the E-LDL particles. For acetylation, the standard protocol of Goldstein et al¹⁴ was used. Lipid peroxidation was excluded by the absence of TBARS.¹⁵ Lipoproteins were stored at 4°C and used within 1 to 2 weeks.

Staining of Foam Cells
SMC were fixed in 10% formaldehyde for 30 minutes at room temperature and intracellular lipids were stained with a saturated solution of oil-red-O for 6 hours.

Quantification of Cholesterol Uptake
Cellular cholesterol uptake was measured by the classic method described by Goldstein et al.¹⁶ Cells were incubated with lipoproteins in the presence of [³H]oleic acid (500 nmol/L; specific activity 1.8 to 2.2x10⁷ cpm/mL) for 12 hours at 37°C. Chromatography of the extracted lipids was performed on silica gel–TLC plates (Machery & Nagel), and radioactivity was detected in a ß-counter (LKB-ß, Beckman Instruments). The oleic acid standard (Sigma) was used for calibration.

Reverse Transcription–Polymerase Chain Reaction of Chemokine and Cytokine mRNA
RNA was isolated from confluent SMC cultures by guanidine isothiocyanate–phenol–chloroform extraction as described by Chomczynski and Sacchi.¹⁷ Reverse transcription and reverse transcription–polymerase chain reaction was conducted as described.^{6 13} Samples lacking cDNA or RNA served as negative controls. Polymerase chain reaction products were run on 1% agarose gels in 1xTBE and stained with ethidium bromide. Amplification of a defined IL-6R sequence by the primers selected was ascertained by a positive signal with HepG2 cells.

Quantification of Chemokines and Cytokines
Chemokines and cytokines were determined by commercial immunoassay (IL-6, MCP-1, RANTES, MIP-1, and MIP-1ß, R&D Biosystems; IL-8, Innogenetics).

Chemotaxis Assay
Monocyte chemotaxis assays were performed as described previously.⁶ Supernatants of E-LDL–treated SMC were assayed in dilutions from 1:1 up to 1:500. As controls, cell-free medium or supernatant dilutions containing a neutralizing monoclonal anti–MCP-1 antibody (1:200) were used (clone 24822.111, IgG1; R&D Biosystems). The chemotactic index was calculated as described previously.⁶

Immunocytochemical Detection of Surface gp130 Expression
Surface expression of gp130 was analyzed on confluent SMC cultures with a PE-labeled anti-gp130 overnight at 4°C (clone AM64, IgG1; PharMingen), as described.¹³ Cells grown in the absence of lipoproteins served as controls.

Proliferation of SMC
SMC proliferation was assayed by [³H]thymidine incorporation into trichloroacetic acid (TCA; 5% wt/vol) precipitable material, as described.¹³ Cells (2x10⁴/mL) were seeded in 24-well culture plates, grown for 24 hours in complete medium, and kept in medium without additives for further 24 hours. After stimulation, cultures were pulsed with [³H]thymidine (Amersham, 2 to 10 µCi/mL) for the final 6 hours of incubation, and TCA-precipitable radioactivity was quantified in a scintillation counter (LKB-ß; Beckman). SMC cultures grown in the presence of 10% human AB-serum served as positive controls. SMC grown in medium alone or in medium containing the enzyme mix used for the preparation of E-LDL served as unstimulated controls.

Detection of Cellular Toxicity and Apoptosis
Cytotoxic effects of E-LDL on SMC were determined by quantification of the reduction of intracellular ATP.⁶ Apoptosis was detected by analysis of DNA fragmentations and by the TUNEL labeling technique, as described.⁶

Statistical Analysis
The significance of differences between control values and the stimulants was determined by the Mann-Whitney U test. Differences were considered significant at a level of P<0.05. The results are expressed as mean±SD. Analysis was performed with SPSS software.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Foam Cell Transformation of SMC Induced by E-LDL
After incubation of human SMC with 50 µg/mL E-LDL for 6 hours, lipid staining with oil-red-O became positive. Native LDL did not invoke detectable foam cell transformation (Figure 1).

View larger version (80K): [in this window] [in a new window]   Figure 1. Foam cell transformation of human SMC after incubation with 50 µg/mL E-LDL (left) but not with native LDL (right), as shown by staining with oil-red-O.

Measurement of cholesterol-oleate confirmed cellular accumulation of the sterol. Accumulation of cholesterol-oleate commenced after 1 hour of incubation with E-LDL, was maximal after 12 hours, and did not increase thereafter. Native LDL was not amassed (Figure 2).

View larger version (14K): [in this window] [in a new window]   Figure 2. Quantification of cholesterol uptake by SMC. Cholesteryl oleate formation was measured 12 hours after incubation of SMC with native LDL, E-LDL, or acetylated (Ac) LDL (each at 25 µg/mL cholesterol). Bars indicate mean value±SD of quadruplicate determinations. *Differences were significant at P<0.02. Results were reproduced in 6 separate experiments.

Selective Induction of MCP-1 mRNA Expression by E-LDL in SMC
E-LDL stimulated a pronounced, time-dependent expression of MCP-1 mRNA in SMC that was expressed after 4 hours, peaked between 12 and 48 hours, and disappeared after 72 hours (Figure 3). MCP-1 mRNA was only weakly detectable in control cells. In contrast, expression of mRNAs encoding the chemokines IL-8, RANTES, or monocyte inflammatory protein-1 or -1ß (MIP-1, MIP-1ß) could not be detected (data not shown).

View larger version (91K): [in this window] [in a new window]   Figure 3. Kinetics of MCP-1 (A) and IL-6 (B) mRNA expression after stimulation of SMC with 50 µg/mL E-LDL. Expression of GAPDH is shown (C). M indicates DNA marker; C, unstimulated control SMC. Lanes represent time of incubation (h) with E-LDL (25 µg/mL).

Concomitantly, MCP-1 was liberated into the culture supernatants. Maximal levels of 1365±215 pg/mL (n=3) were observed after 48 hours of stimulation. Secreted MCP-1 was biologically active, and a typical bell-shaped dose-response curve with a maximal chemotactic index of 3.1 at 10 ng/mL MCP-1 was observed in chemotaxis assays. Specificity was confirmed by a neutralizing anti–MCP-1 antibody, which caused marked reduction of the chemotactic activity. Secretion of IL-8, RANTES, MIP-1, and MIP-1ß remained unaltered.

Induction of gp130 and IL-6 in SMC
Quiescent human vascular SMC expressed scant amounts of gp130 mRNA and no detectable IL-6 receptor (IL-6R) or IL-6 mRNA. Remarkably, E-LDL prominently induced gp130 mRNA. Expression of gp130 was detected after 4 hours of stimulation, peaked at 24 to 48 hours, and vanished thereafter (Figure 4). Basal gp130 expression was undetectable in more than half of the primary SMC cultures analyzed. E-LDL also promoted expression of IL-6 mRNA, which lagged 4 to 8 hours behind the induction of gp130 mRNA (Figure 3).

View larger version (46K): [in this window] [in a new window]   Figure 4. Amplification of gp130 mRNA expression in human vascular SMC by E-LDL. Time-dependent expression of gp130 mRNA after stimulation of 4 different primary SMC cultures (SMC10, SMC18, SMC19, SMC21) with 25 µg/mL E-LDL is shown. Induction of gp130 preceded that of IL-6 by 8 hours. M indicates DNA marker; , unstimulated control.

Surface expression of gp130 detected by immunocytochemistry was weak in unstimulated human vascular SMC (Figure 5, top) and greatly enhanced after stimulation with 50 µg/mL E-LDL for 8 hours (Figure 5, bottom). Prolonged exposure to E-LDL produced no further enhancement of gp130 surface expression.

View larger version (33K): [in this window] [in a new window]   Figure 5. Induction of gp130 surface protein expression by E-LDL as demonstrated by immunocytochemistry. Top, Weak basal gp130 surface expression in unstimulated SMC; bottom, enhanced gp130 expression 8 hours after exposure to 50 µg/mL E-LDL. Experiments were reproduced with 6 different SMC lines.

Effects of IL-6 and Soluble IL-6R on SMC
In atherosclerotic lesions, SMC are present in the immediate vicinity of infiltrating macrophages. E-LDL induced expression and release of IL-6 from human macrophages and promoted shedding of the soluble IL-6 receptor (sIL-6R).⁶ The next experiments were conducted to assess whether IL-6, sIL-6R, or IL-6+sIL-6R had an effect on gp130 expression on SMC and whether this effect would be influenced by the additional presence of E-LDL.

Treatment of SMC with IL-6 (250 ng/mL) alone led to an almost imperceptible induction of gp130 mRNA (Figure 6A). Similarly, sIL-6R (500 ng/mL) alone provoked only a minor effect (Figure 6B). In contrast, simultaneous stimulation with IL-6 (250 ng/mL) and sIL-6R (500 ng/mL) resulted in a sustained, dose-dependent expression of gp130 mRNA (Figure 6C). The most marked induction of gp130 mRNA was, however, observed when human vascular SMC were preincubated with 50 µg/mL E-LDL for 8 hours and then stimulated with the combination of IL-6 and sIL-6R (Figure 6D). This resulted in prominent expression of gp130 mRNA after 8 hours, which was maintained for 24 hours.

View larger version (98K): [in this window] [in a new window]   Figure 6. Differential regulation of gp130 mRNA expression by IL-6 and sIL-6R alone or in combination. Weak induction of gp130 mRNA by IL-6 (A) or sIL-6R alone (B) is shown. Marked induction of gp130 after stimulation with IL-6/sIL-6R is shown (C). Very pronounced induction of gp130 mRNA after 8-hour preincubation of SMC with 25 µg/mL E-LDL followed by stimulation with IL-6/sIL-6R is shown (D). IL-6 and sIL-6R were applied at 500 ng/mL. M indicates DNA marker; C, unstimulated control. Lanes represent time of incubation (h) with stimulants.

Toxicity of E-LDL on Human Vascular SMC
Exposure to 200 to 400 µg/mL E-LDL reduced the cellular ATP content to <10% of untreated control SMC after 48 hours (Figure 7). At E-LDL concentrations <50 µg/mL, cytotoxic effects were observed only after extended incubation (>48 hours). The cytotoxic effects were not due to apoptosis, as determined by the absence of DNA fragmentations and by negative TUNEL stainings (not shown). The presence of 4% human albumin completely abolished cytotoxicity of E-LDL (Figure 7).

View larger version (18K): [in this window] [in a new window]   Figure 7. Cytotoxic effects of E-LDL on human vascular SMC as demonstrated by measurements of cellular ATP. •, Dose-dependent cytotoxicity of E-LDL on SMC; , protective effect of 4% human albumin. Results are given as mean value±SD of 4 separate experiments.

E-LDL Stimulates SMC Proliferation Through 2 Pathways
Albumin was supplemented at 4% to abrogate the cytotoxic effects of E-LDL in the following proliferation assays. E-LDL alone induced moderate dose-dependent proliferation of human vascular SMC, which reached a maximum at 50 µg/mL E-LDL (Figure 8A). Proliferation commenced after 24 hours, and a 4-fold increase of DNA synthesis was measured at 72 hours (Figure 8B). That the increased incorporation of [³H]-thymidine indeed reflected cell multiplication was ascertained in 4 experiments by direct counting of cells after their release by trypsinization.

View larger version (19K): [in this window] [in a new window]   Figure 8. E-LDL induces proliferation of human SMC. A, Moderate dose-dependent mitogenic effect of E-LDL on SMC after 72 hours of exposure; B, time-dependent stimulation of SMC proliferation in presence of 25 µg/mL E-LDL/4% human albumin (black bars) compared with untreated control cells kept in medium with 4% human albumin (striped bars). Depicted are mean±SD of 6 separate experiments, each with triplicate cultures. *Differences were significant at P<0.05.

An antibody against platelet-derived growth factor (PDGF) reduced the E-LDL–dependent proliferative response by 60%. Blocking fibroblast growth factor (FGF)-ß activity reduced proliferation by 25%. Combined application of both antibodies was additive and reduced cell proliferation by 70%. In contrast, antibody against IL-6 was without effect (Figure 9).

View larger version (20K): [in this window] [in a new window]   Figure 9. E-LDL induced proliferative response in the presence (+) or absence (-) of blocking antibodies against PDGF (50 µg/mL), FGF-ß (10 µg/mL), or IL-6 (1:200). Proliferation was measured after incubation with 25 µg/mL E-LDL/4% human albumin for 72 hours. Results are given as mean values of [3H]thymidine incorporation ±SD of 6 separate experiments, each with triplicate cultures for each experimental condition. *Differences were significant at P<0.05.

As reported above, E-LDL induced release of IL-6 and sIL-6R from macrophages and simultaneously provoked upregulation of gp130 on SMC. It is known that IL-6/sIL-6R can stimulate cells expressing gp130.¹⁸ Therefore, in the next experiments, macrophages were incubated with E-LDL (100 µg/mL) for 72 hours, and the supernatants containing 234±65 pg/mL IL-6 and 987±122 pg/mL sIL-6R were harvested. E-LDL was removed by centrifugation, and the supernatants were incubated with SMC. When applied to nonactivated SMC, the supernatants only weakly induced cell proliferation (Figure 10A). However, if SMC were first preincubated with 25 µg/mL E-LDL for 8 hours (to induce gp130), the supernatants provoked a pronounced and sustained proliferative response that was readily apparent after 72 hours (Figure 10B). E-LDL alone was without effect.

View larger version (25K): [in this window] [in a new window]   Figure 10. Supernatants of E-LDL–stimulated macrophages induce proliferation of SMC. A, Proliferation of 3 different SMC isolates after 24-hour stimulation with different dilutions of supernatants from E-LDL–activated macrophages; B, time dependency of proliferative effect. Black bars indicate undiluted macrophage supernatants from E-LDL–stimulated macrophages; striped bars, control cells. Results are given as mean value±SD of 6 separate experiments, each with triplicate cultures. *Differences were significant at P<0.02.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
SMC proliferation is a key event in the pathogenesis of atherosclerosis, occurring subsequent to the insudation of LDL, complement activation, and the infiltration of macrophages and T-lymphocytes. Our results show that E-LDL can promote this process through 2 mechanisms. First, E-LDL directly stimulates proliferation, a property that has been described also for other lipoproteins including VLDL and oxidized LDL.^{19 20 21} We detected no proliferative responses to native LDL, which stands in some disagreement with an earlier study.²⁰ In the absence of macrophages, E-LDL–induced proliferation appeared to ensue through an autocrine pathway involving PDGF and FGF-ß, as indicated from blocking experiments with antibodies. Arterial SMC express PDGF,^{22 23} and the significance of this growth factor in atherosclerosis is supported by the restricted expression of PDGF receptors on the proliferating SMC subset in the intima,²⁴ whereas expression is absent on stationary SMC in the media.²⁵ The rat homologue of human MCP-1 has been linked both to SMC proliferation and migration,²⁶ and the capacity of E-LDL to stimulate MCP-1 production in both macrophages⁶ and SMC is of interest in this context.

The second pathway leading to an SMC-proliferative response integrates the effects of E-LDL on macrophages and on SMC and highlights the central role of IL-6 and sIL-6R. This mechanism is novel and operates through the convergence of 2 events. The first is the release of both IL-6 and its soluble receptor IL-6R from macrophages. The second is the upregulation of gp130, the signal-transducing element of the IL-6 receptor family on SMC provoked by E-LDL.

It is known that IL-6/sIL-6R complexes form spontaneously in solution after their release from cells. The complexes can subsequently bind to and activate cells that express the signal-transducing element gp130. This process, termed transsignaling, is widely operative because gp130 is constitutively expressed on many cell types.¹⁸ SMC are unusual because quiescent SMC express little gp130 but upregulate the molecule when they are stimulated with IL-6/sIL-6R.¹³ This drives the cells into a proliferative state. We have found that E-LDL is a second stimulus that causes upregulation of gp130, thus enhancing the efficiency of the transsignaling circuit in SMC. The finding satisfactorily explains why SMC proliferation occurred with a relatively long lag phase and why relatively low concentrations of IL-6/sIL-6R were required. It is of interest that in early atherosclerotic lesions, local expression of IL-6 has indeed been detected particularly in macrophage-rich regions and in SMC.^{27 28 29}

Foam cell formation is another hallmark of the atherosclerotic lesion. Although many studies have analyzed the effects of modified lipoproteins on macrophage foam cell formation,^{16 30} investigations into the pathways underlying cholesterol uptake by SMC have remained sparse. We found that E-LDL induces foam cell transformation of SMC, albeit to a smaller extent than found with macrophages. This was in line with histological studies that identify the majority of foam cells as macrophages, with SMC contributing a smaller fraction.^{31 32 33}

Selective recruitment of monocytes and T-lymphocytes into early atherosclerotic lesions probably reflects lesional expression of selective chemoattractants.^{34 35} Local producers of MCP-1 are mainly macrophages,³⁴ vascular SMC being additionally involved in the early stages.^{36 37} That E-LDL induced selective production of MCP-1 in SMC is of interest in this context. In accord with immunohistological studies, lower amounts of MCP-1 were liberated by SMC as compared with macrophages.⁶ Other lesional components including terminal complement complexes may also contribute to MCP-1 generation in SMC.³⁸ In vitro, oxidized LDL (ox-LDL) has been shown to be endowed with this capacity, a finding that might attain significance if ox-LDL were present in the lesions in sufficient amounts.³⁹

The more advanced stages of atherosclerosis are characterized by tissue necrosis. E-LDL induced cytotoxic effects on SMC that were more pronounced than those invoked by ox-LDL.²¹ However, in contrast to ox-LDL,⁴⁰ E-LDL did not recognizably trigger apoptosis of SMC. This would be in accord with immunohistochemical studies showing apoptosis of macrophages and T-lymphocytes but not of SMC in the lesions.^{41 42 43} The abolishment of E-LDL toxicity in the presence of 4% human albumin suggested that free fatty acids mediated toxic effects, as has been described for several cell types including lymphocytes, macrophages, and tumor cells.^{44 45} The other biological effects of E-LDL reported here, that is, SMC proliferation and expression of chemokines, were not affected by the addition of albumin.

In sum, our results show that E-LDL is taken up by human vascular SMC and activates these cells to acquire a proinflammatory phenotype. Of particular interest is the finding that the pathways of SMC and macrophage activation by E-LDL may merge at the level of IL-6/s-IL-6R transsignaling, which operates to drive SMC into a proliferative state. The data go further to show that E-LDL is endowed with the prime characteristics of an atherogenic lipoprotein.

	Acknowledgments

 
This work was supported by grants from the Deutsche Forschungsgemeinschaft (Bonn, Germany) and from the Stiftung Rheinland Pfalz for Innovation (Mainz, Germany). We thank Monika Hemmes for excellent technical assistance.

Received October 8, 1999; revision received November 22, 1999; accepted December 2, 1999.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–126.[Free Full Text]

2. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15:551–561.[Free Full Text]

3. Bhakdi S. Complement and atherogenesis: the unknown connection. Ann Med. 1998;30:503–507.[Medline] [Order article via Infotrieve]

4. Bhakdi S, Dorweiler B, Kirchmann R, Torzewski J, Weise E, Tranum-Jensen J, Walev I, Wieland E. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med. 1995;182:1959–1971.[Abstract/Free Full Text]

5. Bhakdi S, Torzewski M, Klouche M, Hemmes M. Complement and atherogenesis: binding of CRP to degraded, non-oxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol. 1999;19:2348–2354.[Abstract/Free Full Text]

6. Klouche M, Gottschling S, Gerl V, Hell W, Husmann M, Dorweiler B, Messner M, Bhakdi S. Atherogenic properties of enzymatically degraded low density lipoprotein: selective induction of MCP-1 and cytotoxic effects on human macrophages. Arterioscler Thromb Vasc Biol. 1998;18:1376–1385.[Abstract/Free Full Text]

7. Klouche M, May A, Hemmes M, Messner M, Kanse SM, Preissner KT, Bhakdi S. Enzymatically modified, non-oxidized LDL induces selective adhesion and transmigration of monocytes and T-lymphocytes through human endothelial cell monolayers. Arterioscler Thromb Vasc Biol. 1999;19:784–793.[Abstract/Free Full Text]

8. Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, Torzewski J, Gabbert HE, Bhakdi S. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol. 1998;18:369–378.[Abstract/Free Full Text]

9. Torzewski J, Torzewski M, Bowyer DE. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998;18:1366–1375.

10. Seifert PS, Hugo F, Tranum Jensen J, Zahringer U, Muhly M, Bhakdi S. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med. 1990;172:547–557.[Abstract/Free Full Text]

11. Katz SS, Small DM. Isolation and partial characterization of the lipid phases of human atherosclerotic plaques. J Biol Chem. 1980;255:9753–9759.[Free Full Text]

12. Guyton JR, Klemp KF. Development of the atherosclerotic core region. Chemical and ultrastructural analysis of microdissected atherosclerotic lesions from human aorta. Arterioscler Thromb. 1994;14:1305–1314.[Abstract/Free Full Text]

13. Klouche M, Bhakdi S, Hemmes M, Rose-John S. Novel path to activation of vascular smooth muscle cells: upregulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol. 1999;163:4583–4589.[Abstract/Free Full Text]

14. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A. 1979;76:333–337.[Abstract/Free Full Text]

15. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A. 1984;81:3883–3887.[Abstract/Free Full Text]

16. Goldstein JL, Ho YK, Brown MS, Innerarity TL, Mahley RW. Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteins. J Biol Chem. 1980;255:1839–1848.[Abstract/Free Full Text]

17. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156–159.[Medline] [Order article via Infotrieve]

18. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J. 1994;300:281–290.

19. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993;260:1655–1658.[Abstract/Free Full Text]

20. Bjorkerud S, Bjorkerud B. Growth-stimulating effect of lipoproteins on human arterial smooth-muscle cells and lung fibroblasts is due to apo B-containing lipoproteins, type LDL and VLDL, and requires LDL receptors. Biochim Biophys Acta. 1995;1268:237–247.[Medline] [Order article via Infotrieve]

21. Bjorkerud B, Bjorkerud S. Contrary effects of lightly and strongly oxidized LDL with potent promotion of growth versus apoptosis on arterial smooth muscle cells, macrophages, and fibroblasts. Arterioscler Thromb Vasc Biol. 1996;16:416–424.[Abstract/Free Full Text]

22. Majesky MW, Benditt EP, Schwartz SM. Expression and developmental control of platelet-derived growth factor A-chain and B-chain/Sis genes in rat aortic smooth muscle cells. Proc Natl Acad Sci U S A. 1988;85:1524–1528.[Abstract/Free Full Text]

23. Nilsson J, Sjolund M, Palmberg L, Thyberg J, Heldin CH. Arterial smooth muscle cells in primary culture produce a platelet-derived growth factor-like protein. Proc Natl Acad Sci U S A. 1985;82:4418–4422.[Abstract/Free Full Text]

24. Rubin K, Tingstrom A, Hansson GK, Larsson E, Ronnstrand L, Klareskog L, Claesson Welsh L, Heldin CH, Fellstrom B, Terracio L. Induction of B-type receptors for platelet-derived growth factor in vascular inflammation: possible implications for development of vascular proliferative lesions. Lancet. 1988;1:1353–1356.[Medline] [Order article via Infotrieve]

25. Ross R, Masuda J, Raines EW, Gown AM, Katsuda S, Sasahara M, Malden LT, Masuko H, Sato H. Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science. 1990;248:1009–1012.[Abstract/Free Full Text]

26. Luo Y, D’Amore PA, Dorf ME. Beta-chemokine TCA3 binds to and activates rat vascular smooth muscle cells. J Immunol. 1996;157:2143–2148.[Abstract]

27. Ikeda U, Ikeda M, Seino Y, Takahashi M, Kano S, Shimada K. Interleukin 6 gene transcripts are expressed in atherosclerotic lesions of genetically hyperlipidemic rabbits. Atherosclerosis. 1992;92:213–218.[Medline] [Order article via Infotrieve]

28. Seino Y, Ikeda U, Ikeda M, Yamamoto K, Misawa Y, Hasegawa T, Kano S, Shimada K. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine. 1994;6:87–91.[Medline] [Order article via Infotrieve]

29. Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis. 1996;127:263–271.[Medline] [Order article via Infotrieve]

30. Heinecke JW, Suits AG, Aviram M, Chait A. Phagocytosis of lipase-aggregated low density lipoprotein promotes macrophage foam cell formation: sequential morphological and biochemical events. Arterioscler Thromb. 1991;11:1643–1651.[Abstract/Free Full Text]

31. Gerrity RG. The role of the monocyte in atherogenesis, I: transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol. 1981;103:181–190.[Abstract]

32. Aqel NM, Ball RY, Waldmann H, Mitchinson MJ. Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis. 1984;53:265–271.[Medline] [Order article via Infotrieve]

33. Watanabe T, Hirata M, Yoshikawa Y, Nagafuchi Y, Toyoshima H. Role of macrophages in atherosclerosis: sequential observations of cholesterol-induced rabbit aortic lesion by the immunoperoxidase technique using monoclonal antimacrophage antibody. Lab Invest. 1985;53:80–90.[Medline] [Order article via Infotrieve]

34. Ylä-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, Witztum JL, Steinberg D. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A. 1991;88:5252–5256.[Abstract/Free Full Text]

35. Hernandez Presa M, Bustos C, Ortego M, Tunon J, Renedo G, Ruiz Ortega M, Egido J. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997;95:1532–1541.[Abstract/Free Full Text]

36. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991;88:1121–1127.

37. Yu X, Dluz S, Graves DT, Zhang L, Antoniades HN, Hollander W, Prusty S, Valente AJ, Schwartz CJ, Sonenshein GE. Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci U S A. 1992;89:6953–6957.[Abstract/Free Full Text]

38. Torzewski J, Oldroyd R, Lachmann P, Fitzsimmons C, Proudfoot D, Bowyer D. Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells: a possible initiating event in atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol. 1996;16:673–677.[Abstract/Free Full Text]

39. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A. 1990;87:5134–5138.[Abstract/Free Full Text]

40. Nishio E, Watanabe Y. Oxysterols induced apoptosis in cultured smooth muscle cells through CPP32 protease activation and bcl-2 protein downregulation. Biochem Biophys Res Commun. 1996;226:928–934.[Medline] [Order article via Infotrieve]

41. Isner JM, Kearney M, Bortman S, Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation. 1995;91:2703–2711.[Abstract/Free Full Text]

42. Bjorkerud S, Bjorkerud B. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability. Am J Pathol. 1996;149:367–380.[Abstract]

43. Kockx MM, De Meyer GR, Muhring J, Bult H, Bultinck J, Herman AG. Distribution of cell replication and apoptosis in atherosclerotic plaques of cholesterol-fed rabbits. Atherosclerosis. 1996;120:115–124.[Medline] [Order article via Infotrieve]

44. Begin ME, Ells G, Horrobin DF. Polyunsaturated fatty acid-induced cytotoxicity against tumor cells and its relationship to lipid peroxidation. J Natl Cancer Inst. 1988;80:188–194.[Abstract/Free Full Text]

45. Hardwick SJ, Carpenter KL, Law NS, Van Der Veen C, Marchant CE, Hird R, Mitchinson MJ. Toxicity of polyunsaturated fatty acid esters for human monocyte-macrophages: the anomalous behaviour of cholesteryl linolenate. Free Radic Res. 1997;26:351–362.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				A. C. Doran, N. Meller, and C. A. McNamara Role of Smooth Muscle Cells in the Initiation and Early Progression of Atherosclerosis Arterioscler Thromb Vasc Biol, May 1, 2008; 28(5): 812 - 819. [Abstract] [Full Text] [PDF]

				H. Loppnow, K. Werdan, and M. Buerke Invited review: Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms Innate Immunity, April 1, 2008; 14(2): 63 - 87. [Abstract] [PDF]

				H.R.S. Girn, N.M. Orsi, and S. Homer-Vanniasinkam An overview of cytokine interactions in atherosclerosis and implications for peripheral arterial disease Vascular Medicine, November 1, 2007; 12(4): 299 - 309. [Abstract] [PDF]

				S. Demyanets, C. Kaun, K. Rychli, G. Rega, S. Pfaffenberger, T. Afonyushkin, V. N. Bochkov, G. Maurer, K. Huber, and J. Wojta The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI 3-kinase and ERK1/2-dependent pathways Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1962 - H1968. [Abstract] [Full Text] [PDF]

				G. O. Angheloiu, J. T. Arendt, M. G. Muller, A. S. Haka, I. Georgakoudi, J. T. Motz, O. R. Scepanovic, B. D. Kuban, J. Myles, F. Miller, et al. Intrinsic Fluorescence and Diffuse Reflectance Spectroscopy Identify Superficial Foam Cells in Coronary Plaques Prone to Erosion Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1594 - 1600. [Abstract] [Full Text] [PDF]

				I. Dobreva, G. Waeber, R. W. James, and C. Widmann Interleukin-8 Secretion by Fibroblasts Induced by Low Density Lipoproteins Is p38 MAPK-dependent and Leads to Cell Spreading and Wound Closure J. Biol. Chem., January 6, 2006; 281(1): 199 - 205. [Abstract] [Full Text] [PDF]

				S. A. Jones Directing Transition from Innate to Acquired Immunity: Defining a Role for IL-6 J. Immunol., September 15, 2005; 175(6): 3463 - 3468. [Abstract] [Full Text] [PDF]

				J. X. Rong, J. Kusunoki, P. Oelkers, S. L. Sturley, and E. A. Fisher Acyl-CoenzymeA (CoA):Cholesterol Acyltransferase Inhibition in Rat and Human Aortic Smooth Muscle Cells Is Nontoxic and Retards Foam Cell Formation Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 122 - 127. [Abstract] [Full Text] [PDF]

				M. Torzewski, P. Suriyaphol, K. Paprotka, L. Spath, V. Ochsenhirt, A. Schmitt, S.-R. Han, M. Husmann, V. B. Gerl, S. Bhakdi, et al. Enzymatic Modification of Low-Density Lipoprotein in the Arterial Wall: A New Role for Plasmin and Matrix Metalloproteinases in Atherogenesis Arterioscler Thromb Vasc Biol, November 1, 2004; 24(11): 2130 - 2136. [Abstract] [Full Text] [PDF]

				S. W. Lindemann, C. C. Yost, M. M. Denis, T. M. McIntyre, A. S. Weyrich, and G. A. Zimmerman Neutrophils alter the inflammatory milieu by signal-dependent translation of constitutive messenger RNAs PNAS, May 4, 2004; 101(18): 7076 - 7081. [Abstract] [Full Text] [PDF]

				J. X. Rong, M. Shapiro, E. Trogan, and E. A. Fisher Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading PNAS, November 11, 2003; 100(23): 13531 - 13536. [Abstract] [Full Text] [PDF]

				M. A. Nowell, P. J. Richards, S. Horiuchi, N. Yamamoto, S. Rose-John, N. Topley, A. S. Williams, and S. A. Jones Soluble IL-6 Receptor Governs IL-6 Activity in Experimental Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein 130 J. Immunol., September 15, 2003; 171(6): 3202 - 3209. [Abstract] [Full Text] [PDF]

				N. Auge, O. Rebai, J. Lepetit-Thevenin, N. Bruneau, J.-C. Thiers, E. Mas, D. Lombardo, A. Negre-Salvayre, and A. Verine Pancreatic Bile Salt-Dependent Lipase Induces Smooth Muscle Cells Proliferation Circulation, July 8, 2003; 108(1): 86 - 91. [Abstract] [Full Text] [PDF]

				J. H. Von der Thusen, J. Kuiper, T. J. C. Van Berkel, and E. A. L. Biessen Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential Pharmacol. Rev., March 1, 2003; 55(1): 133 - 166. [Abstract] [Full Text] [PDF]

				P. Suriyaphol, D. Fenske, U. Zahringer, S.-R. Han, S. Bhakdi, and M. Husmann Enzymatically Modified Nonoxidized Low-Density Lipoprotein Induces Interleukin-8 in Human Endothelial Cells: Role of Free Fatty Acids Circulation, November 12, 2002; 106(20): 2581 - 2587. [Abstract] [Full Text] [PDF]

				C. Kluft, R. Kleemann, and M.P.M. de Maat How best to counteract the enemies? By controlling inflammation in the coronary circulation Eur. Heart J. Suppl., November 1, 2002; 4(suppl_G): G53 - G65. [Abstract] [PDF]

				I. GOUNI-BERTHOLD and A. SACHINIDIS Does the coronary risk factor low density lipoprotein alter growth and signaling in vascular smooth muscle cells? FASEB J, October 1, 2002; 16(12): 1477 - 1487. [Abstract] [Full Text] [PDF]

				B. S. Sachais, A. Kuo, T. Nassar, J. Morgan, K. Kariko, K. J. Williams, M. Feldman, M. Aviram, N. Shah, L. Jarett, et al. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic itinerary, resulting in retention of low-density lipoprotein on the cell surface Blood, May 15, 2002; 99(10): 3613 - 3622. [Abstract] [Full Text] [PDF]

				D. Kielar, W. Dietmaier, T. Langmann, C. Aslanidis, M. Probst, M. Naruszewicz, and G. Schmitz Rapid Quantification of Human ABCA1 mRNA in Various Cell Types and Tissues by Real-Time Reverse Transcription-PCR Clin. Chem., December 1, 2001; 47(12): 2089 - 2097. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Klouche, M. Articles by Bhakdi, S. Search for Related Content PubMed PubMed Citation Articles by Klouche, M. Articles by Bhakdi, S. Related Collections Smooth muscle proliferation and differentiation